Pierre Espenan
Nephrology · Huntington Park, CANPI 1386618304
Payments from drug & device makers
Across 133 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$341
- Bayer$337
- AstraZeneca$303
- Johnson & Johnson$245
- Otsuka America Pharmaceutical, Inc.$223
- Novo Nordisk$218
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,74595%
- Education$1295%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $341 |
| Bayer | 19 | $337 |
| AstraZeneca | 15 | $303 |
| Johnson & Johnson | 10 | $245 |
| Otsuka America Pharmaceutical, Inc. | 8 | $223 |
| Novo Nordisk | 11 | $218 |
| Amgen | 8 | $185 |
| Fresenius USA Marketing, Inc. | 8 | $172 |
| Sanofi-aventis U.S. LLC | 6 | $159 |
| GSK | 7 | $153 |
| Dexcom, Inc. | 4 | $75 |
| Pfizer | 3 | $65 |
| AbbVie | 3 | $64 |
| Novartis | 3 | $60 |
| Boehringer Ingelheim | 2 | $52 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $19 |
| Abbott | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
How this compares
$2,875 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 122 | $53,380 |
| EliquisApixaban | 45 | $48,527 |
| OzempicSemaglutide | 58 | $47,713 |
| JardianceEmpagliflozin | 61 | $38,732 |
| DapagliflozinDapagliflozin Propanediol | 44 | $34,348 |
| VelphoroSucroferric Oxyhydroxide | 13 | $32,453 |
| Lubiprostone | 119 | $28,726 |
| Icosapent Ethyl | 99 | $26,670 |
| RybelsusSemaglutide | 26 | $26,364 |
| JanuviaSitagliptin Phosphate | 22 | $23,191 |
| KerendiaFinerenone | 33 | $22,065 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 83 | $21,566 |
| FarxigaDapagliflozin Propanediol | 35 | $19,229 |
| MounjaroTirzepatide | 12 | $12,923 |
| MeloxicamMeloxicam, Submicronized | 21 | $12,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $218 | $74,07884 claims |
| PfizerEliquis | $65 | $48,52745 claims |
| Boehringer IngelheimJardiance, Tradjenta | $52 | $44,35672 claims |
| Fresenius USA Marketing, Inc.Velphoro | $172 | $32,45313 claims |
| AstraZenecaFarxiga, Brilinta | $303 | $28,02952 claims |
| Lilly USA, LLCMounjaro, Trulicity | $341 | $22,47323 claims |
| BayerKerendia | $337 | $22,06533 claims |
| AbbVieLinzess | $64 | $7,45611 claims |
| GSKShingrix | $153 | $2,18211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.
Other nephrology in Huntington Park
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.